CTU: A Phase 1, Open Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation

  • Park, John (Primary Chief Investigator)
  • Chester, Catherine (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleD3S-001-100
Effective start/end date24/08/2213/07/27